Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report
INTRODUCTION: Currently, approved disease-specific therapies for patients with immunoglobulin (Ig) A nephropathy in Switzerland are scarce. According to the 2024 KDIGO guidelines, current treatments focus on reducing proteinuria and nephron loss using nephroprotective regimens consisting of renin-a...
Saved in:
| Main Authors: | Leonore Ingold, Michael Dickenmann, Thomas Menter, Helmut Hopfer, Patricia Hirt-Minkowski |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2025-06-01
|
| Series: | Swiss Medical Weekly |
| Online Access: | https://smw.ch/index.php/smw/article/view/4435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01) -
Clinical values of serum Gd-IgA1, complement factor H and complement regulatory proteins in IgA nephropathy
by: Zou Mei, et al.
Published: (2025-05-01) -
WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01) -
WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01) -
The Complement System: An Important New Therapeutic Target in IgA Nephropathy
by: Karshana J. Kalyanaraman, et al.
Published: (2024-12-01)